Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced an extraordinary general meeting to be held on December 31, 2025, to approve several framework agreements. These include the 2026 Promotional Services Framework Agreement, the 2026 Auxiliary R&D Services Framework Agreement, and the 2026 Procurement and Sale of Equipment and Materials Framework Agreement. The approval of these agreements is expected to enhance the company’s operational capabilities and strengthen its partnerships, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company based in the People’s Republic of China, focusing on biopharmaceuticals. The company is involved in the development and provision of biopharmaceutical products and services, with a market focus on innovation within the healthcare and pharmaceutical industries.
Average Trading Volume: 642,426
Technical Sentiment Signal: Buy
Current Market Cap: HK$102.3B
Learn more about 6990 stock on TipRanks’ Stock Analysis page.